The most common drug-related treatment-emergent adverse events (AEs) in patients with HER2-low and HER2-ultralow advanced breast cancer were low grade and generally gastrointestinal or hematologic in nature [6,8,56]. Here, ERBB2 is linked to breast carcinoma.